Meropenem and Piperacillin Plasma Concentrations During CRRT

Completed

• Conditions: Sepsis; Antibiotic; Renal Replacement Therapy; Hemolysis; Infection

• Registration Number: NCT04203784
• Lead Sponsor: Karolinska University Hospital

Brief Summary

This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).

Detailed Description

Not available

Study Timeline

• Study Start: 2012-11-01
• Primary Completion: 2016-12-31
• Study Completion: 2016-12-31
• Study First Submitted: 2019-11-03
• Status Verified: 2019-12
• Study First Submitted QC: 2019-12-16
• Last Update Submitted: 2019-12-17
• Study First Posted: 2019-12-18
• Last Update Posted: 2019-12-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

• patients treated in the study ICU and
• simultaneous CRRT and antibiotic treatment with either meropenem or piperacillin-tazobactam.

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma antibiotic concentrations at mid and end of dosing interval	1 week	The percentage of patients having a concentration above the highest MIC (minimal inhibitory concentration) breakpoint for pathogens considered susceptible for the antibiotic.
Relationships between plasma antibiotic concentrations and CRRT dose.	1 week	We will report the correlation between measured plasma concentrations of either antibiotic and the intensity of the CRRT treatment.
Influence of residual diuresis on the measured plasma antibiotic concentrations.	1 week	We will report the correlation between measured plasma concentrations of either antibiotic and residual diuresis.

Trial Locations

Locations (1)

Karolinska University Hospital Solna; 🇸🇪 Stockholm, Sweden